Noronex Limited Logo

Noronex Limited

NRX.AX

(1.2)
Stock Price

0,02 AUD

-91.71% ROA

-107.06% ROE

-2.07x PER

Market Cap.

9.431.685,00 AUD

0% DER

0% Yield

-5953.28% NPM

Noronex Limited Stock Analysis

Noronex Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Noronex Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.44x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-117.15%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-109.91%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Noronex Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Noronex Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Noronex Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Noronex Limited Revenue
Year Revenue Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 105.232 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Noronex Limited Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Noronex Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 0
2017 106.815 100%
2018 349.207 69.41%
2019 312.603 -11.71%
2020 314.178 0.5%
2021 574.748 45.34%
2022 717.311 19.87%
2023 632.519 -13.41%
2024 649.488 2.61%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Noronex Limited EBITDA
Year EBITDA Growth
2016 -810
2017 -207.650 99.61%
2018 -3.266.682 93.64%
2019 -622.432 -424.83%
2020 -695.419 10.5%
2021 -2.174.187 68.01%
2022 -5.694.405 61.82%
2023 -3.391.510 -67.9%
2024 4.284 79266.9%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Noronex Limited Gross Profit
Year Gross Profit Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 105.232 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Noronex Limited Net Profit
Year Net Profit Growth
2016 -813
2017 -207.761 99.61%
2018 -3.267.106 93.64%
2019 -622.792 -424.59%
2020 -695.493 10.45%
2021 -2.148.452 67.63%
2022 -5.546.334 61.26%
2023 -3.355.110 -65.31%
2024 -3.172.432 -5.76%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Noronex Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Noronex Limited Free Cashflow
Year Free Cashflow Growth
2016 -848
2017 -255.327 99.67%
2018 -1.172.770 78.23%
2019 -632.230 -85.5%
2020 -571.661 -10.6%
2021 -2.064.997 72.32%
2022 -5.361.661 61.49%
2023 -3.124.323 -71.61%
2024 -824.667 -278.86%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Noronex Limited Operating Cashflow
Year Operating Cashflow Growth
2016 -848
2017 -255.327 99.67%
2018 -1.122.770 77.26%
2019 -632.230 -77.59%
2020 -571.661 -10.6%
2021 -1.798.405 68.21%
2022 -5.281.661 65.95%
2023 -3.124.323 -69.05%
2024 -824.667 -278.86%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Noronex Limited Capital Expenditure
Year Capital Expenditure Growth
2016 0
2017 0 0%
2018 50.000 100%
2019 0 0%
2020 0 0%
2021 266.592 100%
2022 80.000 -233.24%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Noronex Limited Equity
Year Equity Growth
2016 -812
2017 6.748.459 100.01%
2018 3.314.569 -103.6%
2019 2.041.576 -62.35%
2020 1.346.083 -51.67%
2021 5.459.267 75.34%
2022 4.577.563 -19.26%
2023 2.899.603 -57.87%
2024 3.005.955 3.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Noronex Limited Assets
Year Assets Growth
2016 35
2017 7.605.602 100%
2018 3.447.719 -120.6%
2019 2.118.375 -62.75%
2020 1.514.658 -39.86%
2021 5.719.238 73.52%
2022 5.046.041 -13.34%
2023 3.324.123 -51.8%
2024 3.415.512 2.68%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Noronex Limited Liabilities
Year Liabilities Growth
2016 847
2017 857.143 99.9%
2018 133.150 -543.74%
2019 76.799 -73.37%
2020 168.575 54.44%
2021 259.971 35.16%
2022 468.478 44.51%
2023 424.520 -10.35%
2024 409.557 -3.65%

Noronex Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-2.07x
Price To Sales Ratio
179.26x
POCF Ratio
-2.1
PFCF Ratio
-3.05
Price to Book Ratio
2.19
EV to Sales
171.93
EV Over EBITDA
-5.79
EV to Operating CashFlow
-2.92
EV to FreeCashFlow
-2.92
Earnings Yield
-0.48
FreeCashFlow Yield
-0.33
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.04
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.99
ROE
-1.07
Return On Assets
-0.92
Return On Capital Employed
-1.05
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-59.94
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
8.42
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
1.81
Gross Profit Margin
1
Operating Profit Margin
-59.94
Pretax Profit Margin
-59.73
Net Profit Margin
-59.53

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.06
Return on Tangible Assets
-0.92
Days Sales Outstanding
1708.8
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0.21
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.25
Current Ratio
2.29
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
3005955
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-123165
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Noronex Limited Dividends
Year Dividends Growth

Noronex Limited Profile

About Noronex Limited

Noronex Limited operates as a mineral exploration company. The company primarily explores for base and precious metals, as well as copper deposits. It focuses on Witvlei project comprising two prospecting licences covering an area of approximately 390 square kilometers located in Kalahari Copper Belt, Namibia. The company was formerly known as Lustrum Minerals Limited and changed its name to Noronex Limited in November 2020. Noronex Limited was incorporated in 2015 and is based in Subiaco, Australia.

CEO
Mr. James Thompson B.Com., B.
Employee
0
Address
295 Rokeby Road
Subiaco, 6008

Noronex Limited Executives & BODs

Noronex Limited Executives & BODs
# Name Age
1 Mr. Bruce Hooper
Chief Geologist
70
2 Mr. Rowan Harland
Company Secretary
70
3 Mr. James Thompson B.Com., B.Comm, C.A., CA, FINSIA, L.L.B., LLB
Executive Director
70

Noronex Limited Competitors